Roche tries to pressure Illumina to start talking

Illumina ($ILMN) isn't the only game in town, and Roche could easily find other companies to acquire that are equally advanced in the gene-sequencing field, Roche ($RHHBY) Chairman Franz Humer told his company's shareholders Tuesday. As Reuters reports, Humer spoke during Roche's annual shareholders meeting in a not-so-subtle attempt to increase the pressure on gene-sequencing company Illumina to start talking with Roche about its $5.7 billion hostile bid. For now, Illumina is resisting the unsolicited bid with a "poison pill" strategy, Reuters notes. Meanwhile, some analysts pointed out to Reuters that while there are some alternatives, Illumina may be the best, most advanced acquisition target among them. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.